<?xml-stylesheet type='text/xsl' href='anzctrTransform.xsl'?>
<ANZCTR_Trial requestNumber="367642">
  <stage>Registered</stage>
  <submitdate>30/01/2015</submitdate>
  <approvaldate>2/03/2015</approvaldate>
  <actrnumber>ACTRN12615000195550</actrnumber>
  <trial_identification>
    <studytitle>A Phase 2a Open Label Study to Evaluate the Pharmacokinetics and Safety of Parathyroid Hormone hPTH(1-34) Administered via Transdermal Delivery and Subcutaneous Injection [Forteo Registered Trademark (teriparatide)] in Healthy Postmenopausal Women</studytitle>
    <scientifictitle>A Phase 2a Open Label Study to Evaluate the Pharmacokinetics and Safety of Parathyroid Hormone hPTH(1-34) Administered via Transdermal Delivery and Subcutaneous Injection [Forteo Registered Trademark (teriparatide)] in Healthy Postmenopausal Women</scientifictitle>
    <utrn>U1111-1165-3007 </utrn>
    <trialacronym />
    <secondaryid>Nil known</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Osteoporosis</healthcondition>
    <conditioncode>
      <conditioncode1>Musculoskeletal</conditioncode1>
      <conditioncode2>Osteoporosis</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Metabolic and Endocrine</conditioncode1>
      <conditioncode2>Other metabolic disorders</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Part A
Treatment A: MicroCor Registered Trademark hPTH(1-34) Transdermal System (TDS) 16 mcg single day application, consecutive day cross over
Treatment B: MicroCor Registered Trademark hPTH(1-34) 
TDS 38 mcg single day application, consecutive day cross over
Treatment C: Forteo Registered Trademark teriparatide (rDNA origin) 20 mcg; single subcutaneous injection
Treatment E: MicroCor Registered Trademark hPTH(1-34) Transdermal System model 2 (TDS) 38 mcg single day application, consecutive day cross over. Proprietary internal mechanical design differs between TDS and TDS Model 2.

Part B
Treatment B: MicroCor Registered Trademark hPTH(1-34) 
Transdermal System (TDS) 38 mcg daily application for 28 days
Treatment C: Forteo Registered Trademark teriparatide (rDNA origin) 20 mcg subcutaneous injection daily for 28 days.
Treatment B subjects will have Treatment D MicroCor Registered Trademark placebo Transdermal System (TDS) applied concurrently twice over the 28 days.

Part A participants will not be recruited into Part B. Subjects will complete a daily dosing diary that will be reviewed by the study staff to monitor adherence.</interventions>
    <comparator>MicroCor Registered Trademark placebo Transdermal System (TDS)  will be applied to Treatment B participants concurrently on two days over the 28 day period in Part B.

Forteo Registered Trademark teriparatide (rDNA origin) 20 mcg subcutaneous injection will be used as the comparator.
</comparator>
    <control>Placebo</control>
    <interventioncode>Treatment: Drugs</interventioncode>
    <interventioncode>Treatment: Devices</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Pharmacokinetic primary variables include: Cmax, AUC0-last, AUC0-8, and AUC0-tau. Assessed in plasma. </outcome>
      <timepoint>Part A: Pre-dose, and at 2, 5, 10, 15, 20, 25, 30, 40, 50, 60, 90, 120, 180, 240, 360 minutes after treatment administration.
Part B: Day 1 and Day 28 at Predose and 5, 10, 30, 60, 120, 240, 360 minutes after treatment. </timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Routine Blood chemistry for safety</outcome>
      <timepoint>Part A: Days 1-4, Day 7
Part B: Day 1, 2, 3 4, 5, 6, 7, 10, 12, 14, 17, 19, 21, 24, 26, 28, 42, Day
56</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Any adverse event reported by subject and recorded in CRFs, for example new or worsened clinical conditions, clinically significant laboratory abnormalities; will be followed by study staff over their study participation (Part A 7 days; Part B 56 days.  Any Serious Adverse Events will be followed and reported per industry guidance. </outcome>
      <timepoint>All study days in Part A (7 days) and Part B (56 days)</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>8 point Validated Local Irritation categorical scale </outcome>
      <timepoint>At the time of dosing, and at 2, 8, 24, 48 and 72 hours following removal of MicroCor units or completion of the Forteo Registered Trademark injection.</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Anti- PTH antibody (Part B only) assessed by serum assay. </outcome>
      <timepoint>Pre-dose Day 1, Day 42, Day 56.</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Pharmacokinetic: The secondary pharmacokinetic variables for comparison will include but is not limited to tmax, t1/2,Cmax, Cmin, Cavg, AUC, % Fluctuation, and Relative Bioavailability. Assessed by plasma assay. </outcome>
      <timepoint>Part A: Pre-dose, and at 2, 5, 10, 15, 20, 25, 30, 40, 50, 60, 90, 120, 180, 240, 360 minutes after treatment administration.
Part B: Day 1 and Day 28 at Predose and 5, 10, 30, 60, 120, 240, 360 minutes after treatment. </timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Pharmacodynamics: PINP, CTX and Osteocalcin parameters (for Part B only). Assessed in serum and plasma. </outcome>
      <timepoint>Days 1, 7, 14, 21, 28, 42, 56</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Validated Adhesion scores </outcome>
      <timepoint>MicroCor hPTH(1-34) adhesion will be assessed immediately after
application, 1, 2, 3, 4, 5 minutes (+/-15 seconds).</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Local discomfort by unpublished, proprietary measuring tool</outcome>
      <timepoint>On all dosing days immediately following activation of
MicroCor or injection of Forteo Registered Trademark, and immediately prior to TDS removal.
</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Applicator Performance: The plunger mechanism movement will be assessed by a Corium provided measuring unit. </outcome>
      <timepoint>Movement will be assessed in Part A on Day 7 with 3 consecutive measurements.</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>Inclusion:

Post-menopausal woman, aged 50-85 years old at screening in otherwise good general health as determined by the Investigator.

Agrees to being evaluated for baseline T scores or providing DXA results that are less than 1 year old or subject is
willing to undergo a DXA scan at the time of screening.

Must have no clinically significant findings as determined by the Investigator based on physical examination, 12-lead ECG and vital signs 

Clinical laboratory values at screening, including ionized and total calcium, phosphorus, creatinine, albumin, and
PTH, must be within the normal limits as defined by the clinical laboratory, or are not clinically significant.

Corrected calcium (total calcium normalized) or albumin concentrations must be &lt; upper limit of normal in ref range
at the screening visit.

25-hydroxyvitamin D must be &gt;20 ng/ml at the screening visit.

</inclusivecriteria>
    <inclusiveminage>50</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage>85</inclusivemaxage>
    <inclusivemaxagetype>Years</inclusivemaxagetype>
    <inclusivegender>Females</inclusivegender>
    <healthyvolunteer>Yes</healthyvolunteer>
    <exclusivecriteria>Exclusion:

Has a diagnosis of osteoporosis, defined by bone mineral densitometry T score at any location on the body.

Had a loss of height greater than 5cm (2 inches) supported by medical records or subject self report.

Had recent bone fractures or fragility fractures.

Has an uncontrolled medical condition in the opinion of the Investigator or a controlled medical condition requiring
regular treatment with prescription drugs that would influence calcium, bone metabolism or relevant biomarkers.

Has history of significant chronic disease, cancer or any medical condition known to affect bone metabolism, hepatic or renal disorder requiring medical intervention.

Prior use of PTH replacement therapy or any of its analogs within the previous year.

Current use and/or use within the last year of corticosteroids (eye drops and topical creams are acceptable).

Currently use agents that influence calcium, bone metabolism or relevant biomarkers, such as calcitonins, bisphosphonates, Selective Estrogen Receptor Modulators (SERMs), teriparatide, phenobarbital, phenytoin,
glucocorticoids or anabolic steroid agents. Exceptions are: prior bisphosphate therapy if commenced one year prior to randomization, stable doses of Vitamin D and calcium supplements for at least three months prior to screening and PRN (as needed) use of anti-nausea medication.
</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Randomised controlled trial</allocation>
    <concealment>The study is open-label (concealment is not carried out) with subject enrolment by age range;  approximately 33% in 50-59 years old range and approximately 67% in 60-85 years old range. Subjects are randomised to treatment order in Part A and randomised to treatment allocation in Part B. For each study part, the master randomization schedule will be made of randomly permuted blocks of appropriate sizes, as determined by the statistician producing the master randomization schedules. A separate randomization schedule will be prepared for each study part. A separate randomization schedule will be produced for each age group.</concealment>
    <sequence />
    <masking>Open (masking not used)</masking>
    <assignment>Other</assignment>
    <designfeatures>The study is open-label (concealment is not carried out) with subject enrolment by age range;  approximately 33% in 50-59 years old range and approximately 67% in 60-85 years old range. Subjects are randomised to treatment order in Part A and randomised to treatment allocation in Part B. For each study part, the master randomization schedule will be made of randomly permuted blocks of appropriate sizes, as determined by the statistician producing the master randomization schedules. A separate randomization schedule will be prepared for each study part. A separate randomization schedule will be produced for each age group.</designfeatures>
    <endpoint>Pharmacokinetics</endpoint>
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry>False</patientregistry>
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 2</phase>
    <anticipatedstartdate>6/02/2015</anticipatedstartdate>
    <actualstartdate>16/02/2015</actualstartdate>
    <anticipatedenddate />
    <actualenddate />
    <samplesize>39</samplesize>
    <actualsamplesize />
    <recruitmentstatus>Recruiting</recruitmentstatus>
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate>VIC</recruitmentstate>
    <postcode>3004 - Melbourne</postcode>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Commercial sector/Industry</primarysponsortype>
    <primarysponsorname>Corium International, Inc</primarysponsorname>
    <primarysponsoraddress>235 Constitution Drive
Menlo Park, CA 94025</primarysponsoraddress>
    <primarysponsorcountry>United States of America</primarysponsorcountry>
    <fundingsource>
      <fundingtype>Commercial sector/Industry</fundingtype>
      <fundingname>Corium International, Inc</fundingname>
      <fundingaddress>235 Constitution Drive
Menlo Park, CA 94025</fundingaddress>
      <fundingcountry>United States of America</fundingcountry>
    </fundingsource>
    <secondarysponsor>
      <sponsortype>None</sponsortype>
      <sponsorname />
      <sponsoraddress />
      <sponsorcountry />
    </secondarysponsor>
  </sponsorship>
  <ethicsAndSummary>
    <summary>Phase 2a open label, randomised study to evaluate the pharmacokinetics and safety of MicroCor hPTH(1-34) Administered via Transdermal Delivery and Subcutaneous Injection [Forteo Registered Trademark (teriparatide)] in healthy postmenopausal volunteers</summary>
    <trialwebsite />
    <publication />
    <ethicsreview>Approved</ethicsreview>
    <publicnotes />
    <ethicscommitee>
      <ethicname>Alfred Hospital Ethics Committee</ethicname>
      <ethicaddress>55 Commercial Rd, Melbourne VIC 3004</ethicaddress>
      <ethicapprovaldate>19/12/2014</ethicapprovaldate>
      <hrec>525/14</hrec>
      <ethicsubmitdate>24/11/2014</ethicsubmitdate>
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title>Dr</title>
      <name>Jason Lickliter</name>
      <address>Nucleus Network 5th Floor, Burnet Tower, AMREP
Precinct 89 Commercial Road Melbourne, Victoria, 3004</address>
      <phone>+61 3 9076 8906</phone>
      <fax>+61 (0)3 9076 8911</fax>
      <email>j.lickliter@nucleusnetwork.com.au</email>
      <country>Australia</country>
      <type>Principal Investigator</type>
    </contact>
    <contact>
      <title>Ms</title>
      <name>Vaeling Miller</name>
      <address>Vaeling Miller, Senior Director of Clinical Operations
Corium International, Inc.
235 Constitution Drive
Menlo Park, CA 94025</address>
      <phone>+1 650-298-8255</phone>
      <fax />
      <email>vmiller@coriumintl.com</email>
      <country>United States of America</country>
      <type>Public Queries</type>
    </contact>
    <contact>
      <title>Dr</title>
      <name>Bobby Singh</name>
      <address>Dr Bobby Singh, Vice President Research and Development
Corium International, Inc.
235 Constitution Drive
Menlo Park, CA 94025</address>
      <phone>+1 650-298-8255</phone>
      <fax />
      <email>bobbys@coriumintl.com</email>
      <country>United States of America</country>
      <type>Scientific Queries</type>
    </contact>
    <contact>
      <title>Dr</title>
      <name>Naomi Croll</name>
      <address>Dr Naomi Croll, Project Manager
INC Research
Suite 1, Level 2, 924 Pacific Highway 
Gordon, NSW 2072
</address>
      <phone>+ 61 2 8437 9200 </phone>
      <fax />
      <email>naomi.croll@incresearch.com</email>
      <country>Australia</country>
      <type>Updating Information</type>
    </contact>
  </contacts>
</ANZCTR_Trial>